Further options for the application of immunotherapy in ovarian cancer include a combination of immune-checkpoint inhibitors with chemotherapy or targeted therapy such as anti-angiogenic agents and PARP inhibitors, as well as a combination of immune-checkpoint inhibitors which target different mechanisms in the immune system. This evidence concerns the gene PARP1 and ovarian cancer.